Browse studies

Find your next paid study

21 recruiting studies matching your filters

A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Macular Edema Secondary to Inflammation

Estimated

~$10 – $8,750

Kodiak Sciences IncNCT06990399

Phase 3

A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Macular Edema Secondary to Inflammation

Estimated

~$10 – $8,750

Kodiak Sciences IncNCT06996080

Phase 4

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues. Patients may have impr…

Diabetic Macular Edema (DME)

Estimated

~$10 – $7,500

Retina Consultants of Orange CountyNCT06662994

Phase 2

A Randomized, Open Label, Controlled, Phase 2 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 AAV Gene Therapy Administered Via Subretinal Delivery in Participants With Center Involved Diabetic Macular Edema

Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)

Diabetic Macular Edema

Estimated

~$10 – $7,500

Sierra Eye AssociatesNCT06942520

Phase 2

An Evaluation of the Clinical Usability of the SCD411 Prefilled Syringe as a Proposed Biosimilar to US-licensed Eylea®

This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Rel…

Neovascular (Wet) Age-Related Macular DegenerationRetinal Vein OcclusionDiabetic Macular Edema+1 more

Estimated

~$10 – $8,750

Sam Chun Dang Pharm. Co. Ltd.NCT07501052

Phase 1

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

Treatment of diabetic retinopathy (DR) and diabetic macula edema has included panretinal photocoagulation and intra ocular injections of anti-vascular endothel…

Diabetic Macular Edema

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT06881888

Phase 1

Randomized Trial of Kamuvudine-9 (K9) in DME

The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral pla…

Diabetic Macular Edema

Estimated

~$10 – $7,500

Dr. Bryan StrelowNCT07458061

Phase 1

Randomized, Prospective, Vehicle-Controlled, Phase I/II Clinical Trial to Evaluate the Safety and Feasibility of a Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema

The main aim of the pilot study is to determine preliminary estimates of the safety, tolerability, and comfort of a dexamethasone-eluting therapeutic contact l…

Cystoid Macular Edema

Estimated

~$10 – $7,500

Massachusetts Eye and Ear InfirmaryNCT04225611

Phase 4

A Randomized, Controlled, PRospective Study of the Effectiveness and Safety of the Ocular Therapeutix Dextenza (Dexamethasone Ophthalmic Insert) 0.4 mg for the treatMEnt of Post-operative Inflammation in Patients Who Plan to Undergo Refractive Lens Exchange (RLE)

To investigate the outcomes of patients undergoing bilateral RLE surgery with treatment of dexamethasone intracanilicular insert compared to topical standard c…

Patient PreferencePatient OutcomesPost-Operative Inflammation+2 more

Estimated

~$10 – $7,500

Vance Thompson Vision - MTNCT04549935